All In Biotech

Drug Trial Radar · NCT06685809

A Phase 1 Study of FZ008-145 in Healthy Subjects.

A Phase 1 Study Assessing Safety, Tolerability, Pharmacokinetics and Physiological Response (Pain Tolerance) to Single and Multiple Ascending Doses of FZ008-145 in Healthy Subjects.

Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 176 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

176

Actual

Start

Nov 25, 2024

Primary completion

Apr 14, 2026

Study completion Apr 14, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will be conducted in 5 parts: Part A and Part B (single ascending dose \[SAD\] in solution formulation and tablet respectively), Part D and Part D2 (cold pressor test \[CPT\] to evaluate pain tolerance following single dose), and Part E (multiple ascending doses \[MAD\] in tablet formulation).

Conditions

  • Healthy

Interventions

  • FZ008-145 solutionDrug

    Dose formulation- Oral solution

  • FZ008-145 TabletDrug

    Dose formulation- Oral tablet

  • PlaceboDrug

    Dose formulation- Matching doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety of FZ008-145 solution by number of adverse events (AEs) and treatment-emergent adverse events (TEAEs)Time frame: up to 14 days post first dose administration
  2. To assess the safety of FZ008-145 tablet by number of adverse events (AEs) and treatment-emergent adverse events (TEAEs)Time frame: up to 14 days post first dose administration
  3. Number of participants with changes in laboratory parameters determined as adverse events following oral dose of FZ008-145 solution and FZ008-145 tabletTime frame: up to 14 days post first dose administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research Pty

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.